<DOC>
	<DOC>NCT00255489</DOC>
	<brief_summary>The purpose of this study is to characterize the safety profile of ZD1839 in combination with Palliative thoracic Radiotherapy in patients with non-small cell lung cancer</brief_summary>
	<brief_title>A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Provision of written informed consent Patients requiring low dose palliative thoracic irradiation to a field size of less than or equal to 150cm2 Histologically or cytologically conformed nonsmall cell lung cancer Aged 18 or over Previous thoracic radiotherapy Any condition that may predispose the patient to suffer an individual drugrelaged DLT (dose limiting toxicity) event Known hypersensitivity to any component of study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>